A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Summary
- Eligibility
- for people ages 40 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Schafer Boeder
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Schafer Boeder
Associate Physician, Medicine, Health Sciences. Authored (or co-authored) 9 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- ID
- NCT04255433
- Phase
- Phase 3 Research Study
- Study Type
- Interventional
- Participants
- Expecting 12500 study participants
- Last Updated